Balloon-Occluded Chemoembolization for Liver Cancer: How It Works, What the Evidence Shows, and What Comes Next

Table of Contents

• Key Points
• Background: Why Liver Cancer Treatment Needs Better Options
• What Is B-TACE and How Does It Differ from Conventional TACE?
• How B-TACE Works: The Role of Blood Pressure and Blood Flow
• Balloon-Occluded Arterial Stump Pressure (BOASP): The Key Measurement
• The Impact of Collateral Blood Vessels
• Using Modern Imaging to Predict Treatment Success
• Peripheral Embolization and "Chemical Segmentectomy"
• Clinical Evidence: How Well Does B-TACE Work?
• Tumor Size Matters: Where B-TACE Excels
• Long-Term Outcomes and Retreatment Rates
• Safety Profile and Side Effects
• Limitations of Current Evidence
• Future Directions and Ongoing Research
• What This Means for Patients
• Frequently Asked Questions
• Source Information

Key Points

• B-TACE uses a tiny balloon to temporarily block the tumor's artery, then injects chemotherapy and lipiodol so the drug deposits more densely.
• In a meta-analysis of five studies and 1,166 patients, B-TACE had higher complete response (63.1% versus 53.2%) and objective response (96.1% versus 79.4%) than conventional TACE.
• A European multicenter study found B-TACE's advantage was clearest for tumors 3 to 5 centimeters; smaller and larger tumors showed no significant difference.
• No randomized controlled trial has yet proven that B-TACE helps patients live longer than conventional TACE.
• B-TACE's safety profile is broadly comparable to conventional TACE, but reported risks include biloma, liver abscess, and raised liver enzymes.

Background: Why Liver Cancer Treatment Needs Better Options

Hepatocellular carcinoma (HCC, the most common form of primary liver cancer) is one of the most widespread and deadly cancers in the world. The disease represents a major public health concern, particularly in Asia.

For patients whose liver cancer cannot be removed by surgery, a treatment called transarterial chemoembolization (TACE) is a standard first-line option recommended by medical guidelines. TACE delivers chemotherapy drugs directly into the blood vessels that feed the tumor, then blocks those vessels to cut off the tumor's blood supply.

Conventional TACE (C-TACE) is performed through a small puncture in the groin or wrist. A thin tube called a catheter is guided into the liver artery that supplies the tumor. Doctors then inject a mixture of chemotherapy drugs and a special oily dye called lipiodol. After that, they block the blood vessel using tiny particles. This two-part approach aims to kill tumor cells both by delivering chemotherapy and by cutting off blood flow.

Despite its established role, conventional TACE has significant limitations:

• Tumors are not uniform. The liver has a dual blood supply, from both the hepatic artery and the portal vein. This dual blood supply makes it hard to deliver the drug mixture evenly throughout the tumor.
• As tumors grow larger and more complex, local tumor control becomes less effective.
• The edges of the tumor may not be fully covered, allowing surviving cancer cells or small satellite tumors to persist.
• The chemotherapy mixture can be washed away by blood flow or leak into non-target vessels, reducing effectiveness and increasing the risk of complications, including liver damage.

Even a newer version of TACE that uses drug-eluting beads (DEB-TACE, which releases medication slowly over time) has limitations. Studies suggest that the beads mainly block the arteries feeding the tumor but may not reach the surrounding drainage area, the tumor capsule, or the portal vein territory. As a result, completely eliminating microscopic cancer spread and satellite lesions can be difficult.

These limitations have driven interventional radiologists to develop new techniques. One important advance is balloon-occluded TACE (B-TACE).

What Is B-TACE and How Does It Differ from Conventional TACE?

B-TACE was first described by researchers led by Dr. Irie and has since been refined for clinical use. The technique uses a special microcatheter (a very thin tube) with a tiny inflatable balloon at its tip.

Here is how the procedure works:

1. The doctor guides the microcatheter into the specific artery that feeds the tumor.
2. The balloon is temporarily inflated, which stops blood from flowing forward through that artery.
3. With blood flow halted, the doctor injects the chemotherapy-lipiodol mixture under controlled conditions.
4. The balloon is then deflated, restoring normal blood flow.

This procedure does more than simply block a blood vessel. It actively and reversibly changes the blood flow dynamics in the area around the tumor. Early clinical evidence suggests that B-TACE improves how well the chemotherapy mixture deposits inside the tumor. It also achieves higher rates of complete tumor death compared with conventional TACE, indicating better local tumor control.

Since its introduction, B-TACE has been adopted and further developed at medical centers across Japan, Korea, Europe, and other regions. This has led to variations of the technique, including double-balloon B-TACE for complex blood vessel anatomy and B-TACE combined with drug-eluting beads.

Currently, B-TACE is an important treatment option for liver cancer with difficult blood vessel anatomy, or for tumors that have not responded to or have come back after conventional TACE.

How B-TACE Works: The Role of Blood Pressure and Blood Flow

The superior effectiveness of B-TACE does not come from simply blocking a blood vessel. It comes from precisely and actively changing the blood flow dynamics within the territory fed by the tumor's artery.

When the balloon temporarily blocks the hepatic artery, the blood pressure downstream from the balloon drops. When the doctor then injects the lipiodol-chemotherapy mixture, blood flow in the surrounding normal liver tissue slows down quickly. This happens because the mixture is thick and sticky, and because the pressure difference between the hepatic artery and the portal vein is reduced.

In contrast, tumor blood vessels typically have lower resistance and maintain relatively preserved blood flow. This difference means the chemotherapy mixture is restricted from entering normal liver tissue and instead accumulates inside the tumor.

In conventional TACE without balloon occlusion, high arterial pressure continuously flushes the injected mixture away. This prevents the drug from depositing optimally within the tumor's blood vessels. By reducing the pressure downstream from the balloon, B-TACE lowers the pressure difference between the inflow artery and the blood vessels downstream. This creates a more favorable environment with reduced flow and resistance. As a result, the chemotherapy mixture encounters less washout, penetrates the tumor's blood vessels more effectively, and achieves denser deposition.

Balloon-Occluded Arterial Stump Pressure (BOASP): The Key Measurement

BOASP (balloon-occluded arterial stump pressure) is the central concept for understanding how B-TACE works. BOASP refers to the blood pressure measured in the artery segment downstream from the inflated balloon, after the balloon has been inflated to block forward blood flow.

In a pivotal study, Dr. Irie and colleagues established a quantitative link between BOASP and treatment outcomes. By monitoring pressure in real time, they observed that balloon inflation causes BOASP to drop significantly below normal hepatic arterial pressure levels.

A key finding was that when BOASP falls below a threshold of 64 mmHg, the subsequently injected chemotherapy mixture accumulated much more densely within the tumor. This led to complete tumor death or near-complete tumor death.

However, 64 mmHg should not be regarded as an absolute threshold that applies to all patients. In the available studies, both patients who achieved complete response and those who did not were observed above and below this value. The reproducibility of BOASP measurements and the applicability of this threshold across different patient populations require further investigation.

Several practical limitations should also be recognized:

• BOASP is not routinely measured in clinical practice because of equipment constraints, differences in patient anatomy, and technical complexity.
• There is currently no established guidance on how to proceed when BOASP cannot be reduced below the proposed threshold.

The Impact of Collateral Blood Vessels

The effectiveness of reducing BOASP is not guaranteed. It depends critically on the liver's complex network of collateral arteries (alternative blood vessels that can carry blood around a blockage). This network includes:

• The peribiliary vascular plexus (a network of small blood vessels surrounding the bile ducts)
• Communicating arches between liver lobes and segments, such as the connections near the liver hilum that link the left and right hepatic arteries
• Isolated arteries that run independently of the bile ducts

When a tumor's feeding artery is connected to surrounding vessels through strong collateral pathways, blood can quickly bypass the inflated balloon. This detour maintains a high BOASP, which cancels out the blood flow advantage of the balloon occlusion. In such cases, the outcome of B-TACE may be similar to that of conventional TACE.

Conversely, if the target blood vessel has minimal or underdeveloped collateral connections, balloon occlusion can effectively cause a significant drop in BOASP. This creates the ideal conditions for dense, localized deposition of the chemotherapy mixture.

Therefore, the anatomical location of the occlusion is a key consideration. Research by Matsumoto and colleagues indicates that balloon inflation at specific sites with known large collateral arches often results in a persistently high BOASP (64 mmHg or above). These sites include:

• The main left or right hepatic arteries
• Arteries supplying liver segments S1, S4, and S8

This suggests that B-TACE may be less effective for tumors primarily fed by arteries in these locations.

Using Modern Imaging to Predict Treatment Success

Modern imaging techniques are used during the procedure. These include cone-beam computed tomography (CBCT) and computed tomography during arterial portography (CTAP). These techniques provide an effective way to visualize the blood flow effects of balloon occlusion in real time.

For example, Dr. Ishikawa and colleagues found that after balloon occlusion, most liver cancer nodules showed increased pixel values on CBCT. These increased pixel values correlated with denser lipiodol deposition.

A study by Dr. Yoshimatsu and colleagues demonstrated an effect of balloon occlusion. After balloon occlusion, the area of portal venous perfusion defect around the tumor on CTAP images often shrinks significantly. A portal venous perfusion defect is an area of the liver that appears to be receiving reduced blood flow from the portal vein.

This finding has important physiological meaning. It confirms that reducing BOASP alters the pressure balance between the hepatic artery and the portal vein. The drop in arterial pressure enables portal venous blood to flow more easily into the liver sinusoids (tiny blood channels) surrounding the tumor. This effectively fills in areas that were previously undersupplied with blood.

This phenomenon visually confirms the blood flow impact of B-TACE and suggests a protective mechanism for non-tumor liver tissue. Enhanced portal blood flow may compensate for the temporarily blocked arterial supply to the treated area, potentially reducing injury to healthy liver tissue.

Conversely, if the CTAP defect remains unchanged after balloon occlusion, this strongly suggests the presence of rich collateral vessels that maintain a high BOASP. Therefore, the absence of change on CTAP can serve as an imaging marker for predicting poor accumulation of the chemotherapy mixture.

Peripheral Embolization and "Chemical Segmentectomy"

With the balloon acting as a reliable valve that prevents backward flow, the doctor can inject the chemotherapy mixture at a higher pressure. This significantly reduces the risk of the mixture flowing backward into non-target vessels.

This allows a high concentration of the mixture to penetrate deeper under pressure, blocking the tumor's feeding arterioles (small arteries) and even capillary beds. Once the blocking is sufficiently thorough, lipiodol can completely fill the tumor nodule and deposit in the surrounding liver sinusoids.

This results in dense lipiodol staining of an entire subsegment or segment of the liver on imaging. The result mimics a surgical "segmentectomy" (surgical removal of a liver segment). This process is therefore called "chemical segmentectomy."

Studies have shown that lesions achieving this lipiodol subsegmental cast have significantly higher rates of complete tumor death under the microscope and better long-term local tumor control.

Clinical Evidence: How Well Does B-TACE Work?

High-level evidence from randomized controlled trials (RCTs) is still lacking. RCTs are studies where patients are randomly assigned to different treatments. Many observational studies provide compelling evidence that B-TACE is an effective treatment for liver cancer.

In terms of short-term effectiveness, such as the complete response (CR) rate and objective response rate (ORR), B-TACE shows a benefit signal. A complete response means the tumor can no longer be detected on imaging. An objective response includes both complete and partial responses (where the tumor shrinks significantly).

A meta-analysis (a study that combines results from multiple studies) by Dr. Liu and colleagues included five retrospective studies involving 1,166 patients. This analysis compared the effectiveness of B-TACE with conventional TACE. Four of the five studies were conducted in East Asia and one in Europe.

Key details about the patients in these studies:

• All enrolled patients had early-stage or intermediate-stage liver cancer.
• Average tumor size ranged from 2.5 to 5.0 centimeters.
• Liver function was classified as Child-Pugh class A or B (meaning the liver was still functioning reasonably well).
• Chemotherapy regimens varied across studies and included miriplatin, cisplatin, epirubicin, and doxorubicin combined with mitomycin C.
• Three studies assessed tumor response using the Liver Cancer Study Group of Japan treatment-effect criteria, while two used the modified Response Evaluation Criteria in Solid Tumors (mRECIST).

Four studies reported better tumor response with B-TACE than with conventional TACE. The remaining study found no statistically significant difference overall. However, subgroup analysis showed a benefit of B-TACE in tumors measuring 3 to 5 centimeters.

Compared with conventional TACE, the meta-analysis of these five studies revealed:

• B-TACE had a higher complete response rate: 63.1% versus 53.2% (relative risk 1.21; 95% confidence interval 1.04 to 1.42).
• B-TACE had a higher objective response rate: 96.1% versus 79.4% (relative risk 1.23; 95% confidence interval 1.09 to 1.38).

These results mean that about 63 in 100 patients treated with B-TACE achieved a complete response, compared with about 53 in 100 patients treated with conventional TACE. The confidence intervals indicate that these differences are unlikely to be due to chance alone.

Tumor Size Matters: Where B-TACE Excels

Tumor size is an important factor influencing how well B-TACE works. A European multicenter retrospective study by Dr. Golfieri and colleagues, which used propensity score matching (a statistical method that makes treatment groups more comparable), revealed a clear "size effect" in favor of B-TACE.

For liver cancer lesions measuring 3 to 5 centimeters in diameter:

• The complete response rate was significantly higher in the B-TACE group than in the conventional TACE group (72.3% versus 54.1%, P = 0.047).

For lesions smaller than 3 centimeters:

• The complete response rates of both techniques were comparable (56.3% for B-TACE versus 61.9% for conventional TACE, P = 0.680). This is likely because small lesions can already be effectively treated with highly selective conventional TACE.

For lesions larger than 5 centimeters:

• Both techniques showed low complete response rates that were not significantly different. This suggests that excessive tumor burden may require combination with other therapies.

These findings suggest that B-TACE may be an ideal choice for medium-sized liver cancer lesions measuring 3 to 5 centimeters.

Long-Term Outcomes and Retreatment Rates

Although confirmation of an overall survival benefit awaits randomized controlled trial results, existing observational studies suggest promising survival outcomes with B-TACE.

Dr. Irie and colleagues reported 1-, 3-, and 5-year survival rates of 96.4%, 60.3%, and 31.1%, respectively, in the B-TACE group. They identified B-TACE as an independent favorable factor for improved overall survival.

A propensity score-matched study further revealed a prolonged median time to local tumor progression: 38 months for B-TACE versus 24 months for conventional TACE.

In a group of patients who achieved complete response through B-TACE, conventional TACE, or drug-eluting bead TACE (DEB-TACE), the median local recurrence-free periods were:

• B-TACE: 39.3 months
• Conventional TACE: 12.9 months
• DEB-TACE: 9.1 months

Additionally, a multicenter study conducted across five European centers reported a median local recurrence-free period of 31.0 months and a median overall survival of 50.0 months.

A study by Dr. Kim and colleagues focused on patients whose liver cancer had not responded to conventional TACE or had come back after treatment. In these challenging cases, B-TACE used as salvage therapy achieved a 100% response rate. It also significantly extended the time to tumor progression compared with the last conventional TACE treatment (4.4 months versus 2.7 months).

B-TACE also has advantages in reducing the need for retreatment. The study by Dr. Golfieri and colleagues revealed that patients treated with B-TACE had a lower retreatment rate within the first 6 months compared with patients treated with conventional TACE.

Safety Profile and Side Effects

B-TACE has a broadly comparable overall safety profile to conventional TACE. However, non-target or excessive peripheral embolization (blocking blood vessels beyond the intended area) can injure the peribiliary plexus (the network of blood vessels around the bile ducts). This can cause biloma (a collection of bile outside the bile ducts) or hepatic abscess (a pocket of infection in the liver).

Post-embolization syndrome (PES) is a common group of symptoms that occurs after TACE procedures. In the studies reviewed, PES symptoms included:

• Nausea: reported in 8 of 49 B-TACE patients versus 5 of 48 conventional TACE patients in one study; 14 of 50 versus 9 of 50 in another study.
• Fever: reported in 27 of 49 B-TACE patients versus 20 of 48 conventional TACE patients in one study; 37 of 50 versus 30 of 50 in another study.
• Pain: reported in 18 of 49 B-TACE patients versus 13 of 48 conventional TACE patients in one study; 7 of 50 versus 8 of 50 in another study.

In terms of liver enzyme changes, one study reported ALT (alanine aminotransferase, a liver enzyme) elevation of grade 3 or higher in 14.3% of B-TACE patients versus 8.3% of conventional TACE patients. Another study reported grade 3 or higher ALT elevation in 18% of B-TACE patients versus 6% of conventional TACE patients.

Other complications reported in the studies included:

• Biloma: 1 case in 28 B-TACE patients versus 0 in 49 conventional TACE patients in one study.
• Liver abscess: 6% (3 of 50) in B-TACE patients versus 0 in 50 conventional TACE patients in one study; 2 of 91 in B-TACE patients versus 0 in 91 conventional TACE patients in another study.
• Pseudoaneurysm (a bulge in a blood vessel wall): 1 of 91 B-TACE patients versus 0 of 91 conventional TACE patients in one study.

In one study, the Child-Pugh score (a measure of liver function) increased by 2 or more points in 7.7% of B-TACE patients versus 5.5% of conventional TACE patients. In another study, ALT levels at 1 day after treatment were 249 U/L (range 19 to 1,491) in B-TACE patients versus 190 U/L (range 9 to 2,425) in conventional TACE patients.

Limitations of Current Evidence

The current evidence for B-TACE has several important limitations that patients and doctors should understand.

First, no randomized controlled trial has yet proven that B-TACE provides a survival advantage over conventional TACE. The available studies are observational, meaning patients were not randomly assigned to treatment groups. This type of study design cannot prove cause and effect.

Second, the proposed BOASP threshold of 64 mmHg is not universally reproducible or routinely available. Both complete responders and non-complete responders have been observed above and below this value. The applicability of this threshold across different patient populations requires further investigation.

Third, BOASP is not routinely measured in clinical practice because of equipment constraints, anatomical variability, and technical complexity. There is currently no established guidance on how to proceed when BOASP cannot be reduced below the proposed threshold.

Fourth, the effectiveness of reducing BOASP depends critically on the liver's complex network of collateral arteries. When strong collateral pathways exist, blood can quickly bypass the inflated balloon, maintaining a high BOASP and canceling out the hemodynamic advantage of balloon occlusion.

Fifth, clinical benefit is most plausible in carefully selected patients. These are patients with preserved liver function. These patients have a limited tumor burden that can be treated with segmental treatment. These patients also have anatomy in which collateral inflow does not prevent a meaningful pressure reduction.

Future Directions and Ongoing Research

The review authors identify several priorities for future research on B-TACE:

1. Standardized technical endpoints: Researchers need to agree on how to measure and report the technical aspects of the procedure.
2. Prospective randomized comparisons: Studies where patients are randomly assigned to B-TACE or conventional TACE are needed to prove whether B-TACE improves survival.
3. Validated selection criteria: Doctors need clear guidelines for identifying which patients will benefit most from B-TACE.
4. Imaging-based hemodynamic prediction: Using imaging techniques to predict how blood flow will respond to balloon occlusion before the procedure.
5. Rigorously designed combinations with systemic or other locoregional therapies: Testing B-TACE in combination with other treatments, such as immunotherapy or targeted therapy.

The authors also note that variations of the technique continue to develop. These include double-balloon B-TACE for complex vascular anatomy and B-TACE combined with drug-eluting beads.

What This Means for Patients

If you or a loved one has been diagnosed with liver cancer that cannot be removed by surgery, here are the key points to discuss with your medical team:

1. Ask whether B-TACE might be an option for your specific tumor. It appears most beneficial for tumors measuring 3 to 5 centimeters.
2. Discuss your liver function. B-TACE appears most beneficial in patients with preserved liver function (Child-Pugh class A or B).
3. Ask about the blood supply to your tumor. If your tumor is fed by arteries with well-developed collateral connections, B-TACE may not provide additional benefit over conventional TACE.
4. Understand that while B-TACE shows promising results in observational studies, no randomized controlled trial has yet proven that it helps patients live longer compared with conventional TACE.
5. Discuss the risks and benefits. B-TACE has a broadly comparable safety profile to conventional TACE, but carries a risk of bile duct injury, biloma, and liver abscess.
6. Ask whether your treatment center has experience with B-TACE and whether they measure BOASP during the procedure.
7. Inquire about clinical trials. The review authors emphasize that randomized controlled trials are needed and may be available at some centers.

The review authors conclude that B-TACE represents an important therapeutic option for liver cancer with difficult vascular anatomy, or for tumors that are refractory or recurrent after conventional TACE. However, they emphasize that clinical benefit is most plausible in carefully selected patients. The technique is not universally superior to conventional TACE, and patient selection remains critical.

Frequently Asked Questions

What is B-TACE and how is it different from conventional TACE?

B-TACE is a liver cancer treatment using a microcatheter with a tiny balloon at its tip. The balloon is temporarily inflated to block blood flow in the artery feeding the tumor, then chemotherapy and lipiodol are injected. Conventional TACE injects the same mixture without balloon occlusion, so blood flow can wash the drug away before it deposits in the tumor.

Which patients might benefit most from B-TACE?

Observational studies suggest B-TACE may help patients with preserved liver function (Child-Pugh class A or B) and tumors measuring 3 to 5 centimeters. It may also be an option for tumors with difficult blood vessel anatomy, or tumors that did not respond to or returned after conventional TACE. Benefit is most plausible in carefully selected patients whose tumor blood supply can be effectively blocked.

Does B-TACE help patients live longer than conventional TACE?

No randomized controlled trial has yet proven that B-TACE helps patients live longer than conventional TACE. The available evidence comes from observational studies, which cannot prove cause and effect. One study reported 1-, 3-, and 5-year survival rates of 96.4%, 60.3%, and 31.1% with B-TACE, but randomized trials are still needed to confirm any survival advantage.

What does the 64 mmHg BOASP threshold mean?

BOASP is the blood pressure measured downstream from the inflated balloon. In one pivotal study, when BOASP fell below 64 mmHg, the chemotherapy mixture accumulated more densely in the tumor, leading to complete or near-complete tumor death. However, 64 mmHg is not an absolute threshold: complete responders and non-responders have been observed both above and below this value.

What are the risks and side effects of B-TACE?

B-TACE has a broadly comparable safety profile to conventional TACE. Post-embolization syndrome is common, including nausea, fever, and pain. Reported complications include biloma, liver abscess, pseudoaneurysm, and raised liver enzymes. Non-target embolization can injure the bile duct network. In one study, liver abscess occurred in 6% of B-TACE patients versus 0% of conventional TACE patients.

How well does B-TACE work for tumors of different sizes?

A European multicenter study found that for tumors 3 to 5 centimeters, complete response was higher with B-TACE than conventional TACE (72.3% versus 54.1%). For tumors under 3 centimeters, response rates were similar. For tumors over 5 centimeters, both techniques showed low complete response rates, suggesting larger tumors may need combination with other therapies.

What should I ask my medical team about B-TACE?

Ask whether B-TACE might be an option for your tumor, especially if it measures 3 to 5 centimeters. Discuss your liver function and your tumor's blood supply, since strong collateral vessels may reduce any added benefit. Ask about risks including bile duct injury, biloma, and liver abscess, whether your center measures BOASP, and whether clinical trials are available.

When should a patient with liver cancer that cannot be removed by surgery seek a second opinion about B-TACE versus conventional TACE?

A second opinion is worth seeking when the tumor measures 3 to 5 centimeters, since B-TACE achieves higher complete response rates than conventional TACE in that size range, while results are comparable below 3 centimeters and poor above 5 centimeters. It also matters if liver function is preserved (Child-Pugh A or B), if the tumor is fed by arteries with strong collateral connections, or if cancer returned after conventional TACE. No randomized trial has yet proven B-TACE extends survival, so confirming whether it fits your anatomy and liver function is reasonable. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Balloon-Occluded Transarterial Chemoembolization for Hepatocellular Carcinoma: Technical Rationale, Current Evidence, and Future Directions.

Authors: Jia X, Chen Y, Cui X, Tian Y, Feng D, Wang W.

Author affiliation: Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China

Journal: Journal of Hepatocellular Carcinoma

Publication details: 2026; Volume 13; Article 622393

DOI: 10.2147/JHC.S622393

Received: 6 May 2026 | Accepted: 13 August 2026 | Published: 28 August 2026

Note: This patient-friendly article is based on peer-reviewed research. The original article is an open-access review published under a Creative Commons Attribution-NonCommercial 4.0 International License. This translation is intended for educational purposes and should not replace consultation with a qualified healthcare provider.